Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “DNA Damage”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Very early researchWithdrawnNCT06246786
What this trial is testing

Breast/Cyclosporin A/TNBC (Triple Negative Breast Cancer)

Who this might be right for
Triple Negative Breast CancerDNA Damage Repair Deficiency
Virginia G. Kaklamani
Early research (Phase 1)WithdrawnNCT06719973
What this trial is testing

Phase 1 Study of M9466 Combined With Carboplatin and Platinum-based Anticancer Therapy (DDRiver 521)

Who this might be right for
Advanced Solid Tumors
EMD Serono Research & Development Institute, Inc.
Not applicableLooking for participantsNCT06990841
What this trial is testing

Comparison of Two Different Sperm Processing Methods and Their Effects on Sperm DNA Fragmentation and Embryo Development

Who this might be right for
DNA DamageDNA Strand BreaksSperm DNA Fragmentation
Richard Kordus, PhD, HCLD (ABB) 50
Not applicableEnded earlyNCT00523471
What this trial is testing

Blood Test to Measure DNA Damage in Blood

Who this might be right for
Prostate Cancer
AHS Cancer Control Alberta 40
Testing effectiveness (Phase 2)Active Not RecruitingNCT04550494
What this trial is testing

Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair Variations

Who this might be right for
Anatomic Stage III Breast Cancer AJCC v8Anatomic Stage IV Breast Cancer AJCC v8Castration-Resistant Prostate Carcinoma+28 more
National Cancer Institute (NCI) 29
Very early researchUnknownNCT04781868
What this trial is testing

Multi-Nutrient Supplement for Radio-Protection

Who this might be right for
Oxidative StressDNA Damage, Radiation InducedRadiation Exposure
McMaster University 30
Testing effectiveness (Phase 2)Ended earlyNCT04030559
What this trial is testing

Niraparib Before Surgery in Treating Patients With High Risk Localized Prostate Cancer and DNA Damage Response Defects

Who this might be right for
ATM Gene MutationBRCA1 Gene MutationBRCA2 Gene Mutation+14 more
University of California, Davis 11
Not applicableUnknownNCT03677414
What this trial is testing

Analysis of Androgene Receptors Axis and DNA Damage Repair Genes in Patients With Prostate Cancer

Who this might be right for
Prostatic Neoplasms
Medical University of Graz 59
Testing effectiveness (Phase 2)Active Not RecruitingNCT05515575
What this trial is testing

Niraparib in People With Soft Tissue Sarcoma Who Have Changes in Their Tumor DNA

Who this might be right for
Sarcoma,Soft TissueSarcoma Uterus
Memorial Sloan Kettering Cancer Center 8
Early research (Phase 1)Study completedNCT03022409
What this trial is testing

Investigate Biomarker Effects of Pre-Surgical Treatment With DNA Damage Repair (DDR) Agents in Patients With Head and Neck Squamous Cell Carcinoma (HNSCC).

Who this might be right for
Head and Neck Squamous Cell Carcinoma
AstraZeneca 21
Not applicableStudy completedNCT03250715
What this trial is testing

Effects of Low Level Laser Therapy on Functional Capacity and DNA Damage of Patients With Chronic Kidney Failure

Who this might be right for
Low-Level Light TherapyRenal Insufficiency, ChronicRenal Dialysis+1 more
Federal University of Health Science of Porto Alegre 28
Very early researchEnded earlyNCT03251872
What this trial is testing

Olaparib for PAH: a Pilot Study

Who this might be right for
Pulmonary Arterial Hypertension
Laval University 6
Not applicableStudy completedNCT03944421
What this trial is testing

The Effects of Replacing Red and Processed Meat With Quorn on Biomarkers of Gut Health

Who this might be right for
Colorectal Cancer
Northumbria University 20
Testing effectiveness (Phase 2)Looking for participantsNCT05536128
What this trial is testing

Evaluating the Efficacy and Safety of Fulvestrant Plus DNA Damage Repair Inhibitors After a CDK4/6 Inhibitor

Who this might be right for
Advanced Breast Cancer
Seoul National University Hospital 64
Not applicableStudy completedNCT00496613
What this trial is testing

Chemotherapy-Induced Changes to Cognition and DNA in Breast Cancer Survivors

Who this might be right for
Breast CancerLong-Term Survivors
Memorial Sloan Kettering Cancer Center 200
Not applicableStudy completedNCT06314633
What this trial is testing

Socioeconomic Determinants of the Chemical Exposome and Its Genotoxic Effects in Children

Who this might be right for
Healthy Volunteer Children
Institut Cancerologie de l'Ouest 149
Not applicableUnknownNCT04801576
What this trial is testing

In Vivo Assessment of Geno- and Cytotoxicity of Fluoridated Toothpastes and Mouthrinses on Buccal Epithelial Cells

Who this might be right for
DNA Damage
University of Split, School of Medicine 40
Not applicableStudy completedNCT05141539
What this trial is testing

Rehabilitation Assessment and Progress Tracking System Based on Video Images for Dysphagic Patients

Who this might be right for
HealthyHead and Neck Cancer
Mahidol University 30
Early research (Phase 1)Not Yet RecruitingNCT06614751
What this trial is testing

A PARG Inhibitor DAT-2645 Monotherapy in Patients with Advanced/Metastatic Solid Tumors Harboring BRCA1/2 Loss of Function Alterations And/or Other Defects in the DDR Pathway

Who this might be right for
Solid CancersBRCA MutationHRD Cancer+8 more
Danatlas Pharmaceuticals Co., Ltd 112
Testing effectiveness (Phase 2)Active Not RecruitingNCT03330847
What this trial is testing

To Assess Safety and Efficacy of Agents Targeting DNA Damage Repair With Olaparib Versus Olaparib Monotherapy.

Who this might be right for
Metastatic Triple Negative Breast Cancer
AstraZeneca 273
Next Page